The current treatment of post-traumatic stress disorder (PTSD), phobias and other anxiety disorders, remains insufficient particularly in producing long-lasting full symptom control. Dysfunctional fear processing is common in these disorders, including a deficiency in fear-inhibitory mechanisms and impairment in the ability to discriminate between safety and danger cues.
The current treatment of post-traumatic stress disorder (PTSD), phobias and other anxiety disorders, remains insufficient particularly in producing long-lasting full symptom control. Dysfunctional fear processing is common in these disorders, including a deficiency in fear-inhibitory mechanisms and impairment in the ability to discriminate between safety and danger cues.
Research has aimed to elucidate brain circuitries, neurotransmitters and downstream signaling pathways important in the alleviation of aberrant fear, with a specific focus on mechanisms modulating fear memory and its behavioral expression. MicroRNAs (miRNA) as "fine tuners" of gene expression at the post-transcriptional level have emerged as critical regulators of such mechanisms important in both, the generation and the inhibition of fear memories. Along these lines, abnormal expression of miRNAs has been associated with different fear-related disorders.
After providing an updated overview on the involvement of miRNAs in fear learning mechanisms, we summarize and discuss in particular those studies in which the implication of miRNAs in successful inhibition of fear has been explored. For a better overview, we dissociate the different modes of fear alleviation investigated in this regard and present studies in rodents demonstrating that specific miRNAs are involved in the destabilization of fear by interfering with consolidation/reconsolidation mechanisms or that they are associated with the generation of fear extinction or safety learning. Finally, we discuss the potential of miRNAs as biomarkers and novel therapeutic targets, as well as the challenges involved in applying the discovered mechanisms in the development of improved treatments of fear-and trauma-related disorders.
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| INTRODUCTION
Fear is defined as the physiological and behavioral response to specific stimuli triggered by the actual presence of a threat. 1, 2 In pathological fear, the fear/trauma stimuli trigger an inappropriate response occurring with an intensity to cause distress and functional impairment. 3 The main characteristics associated with fear-related disorders, including phobias, post-traumatic stress disorder (PTSD) and others, are excessive fear reactions, often triggered by specific objects, situations or internal and external cues in the absence of any real threat or danger. [4] [5] [6] [7] Fear-related disorders are distinctly heterogeneous, and with a lifetime prevalence of up to 28%, they represent the most common psychiatric disorders that affect the western world, and are consequently associated with a large economic burden. [8] [9] [10] [11] Current treatment options aimed at reducing fear and PTSD symptoms include the use of various pharmacological and psychotherapeutic interventions; however, up to 40% of patients exhibit only partial long-term benefit and a majority fail to achieve complete remission. [12] [13] [14] The use of drugs and/or psychotherapeutic interventions, such as extinction-based exposure therapy (EBT), aim to help patients overcome their maladaptive states. However, limitations including delayed onset of therapeutic benefit, high dropout rates, increased risk of drug dependence (in the case of benzodiazepines) and the presence of large proportions of "non-responders" are commonly associated with these disorders. [15] [16] [17] Furthermore, pharmacological interventions mainly aim to treat patients' symptoms and in most cases do not address the causal aspects of these disorders. In light of these shortcomings, current research aims at increasing the understanding of the underlying molecular mechanisms associated with fear-and trauma-related disorders to develop better diagnostic and therapeutic interventions. The alleviation of fear involves different mechanisms that can lead to acute or sustained fear relief. 18 This fear relief can be mediated either via exposure to the fearful stimuli, as in EBT, leading to the formation of a new fear-inhibitory memory and/or disruption of fear-memory reconsolidation, or via the learning of safety cues (safety learning). It may also be achieved without exposure, through erasure or forgetting of the fear ( Figure 1 ). 
| MIRNA BIOGENESIS AND FUNCTION
Since the discovery of miRNAs and their cellular functions, they have become one of the most studied mechanisms of post-transcriptional complementary seed sequence. 49 Comprising 1% to 2% of the genome with over 5000 transcripts described in humans, 50 miRNAs can target hundreds of genes, thus simultaneously controlling multiple biological processes. It is thought that miRNAs regulate up to 60% of the protein-coding genome. 51 MiRNA biogenesis, function and turnover have been the subject of detailed reviews (see References 49, [51] [52] [53] ).
For the purpose of this review, we will briefly summarize these processes ( Figure 3 ). MiRNAs are transcribed as precursor molecules in a dark chamber. 54 It was later shown that the miRNA cluster miR-183/96/182 provides a protective role in these retinal neurons. 55 It was also found that some miRNAs whose expression did not change FIGURE 2 Preclinical and clinical strategies to reveal the functional impact of miRNAs in human brain disorders. To reveal the functional implications of miRNAs in fear-and trauma-related disorders, data are collected from various sources, including preclinical animal models and clinical studies. Utilizing human samples, many studies investigated post-traumatic stress disorder (PTSD) patients (eg, following a return from an active warzone), examining DNA for the presence of single nucleotide polymorphisms via genome-wide association studies (GWAS) or profiling blood samples for aberrant expression of miRNAs. The use of preclinical rodent models of fear-and trauma-related behaviors allows for miRNA profiling from distinct brain regions via highthroughput methods, including RNA sequencing. This also allows for the testing of causality with regard to exogenous manipulation of miRNA candidates. Validating miRNA expression in peripheral compartments such as blood allows for diagnostic biomarker discovery. Combining various methodologies of preclinical and clinical research to fully elucidate the critical role of candidate miRNAs in these debilitating disorders is a promising strategy in developing novel therapeutic targets and/or biomarkers of fear-and trauma-related disorders and revealed miRNA half-life ranges from relatively short (5 days) to more stable, long-term expression (12 days in the case of miR-208). 56 
| MIRNA IN NEURONAL PLASTICITY AND LEARNING AND MEMORY
The role of miRNAs in neuronal plasticity and learning and memory has been bolstered by numerous studies to date (for detailed reviews, see References [57] [58] [59] ). The ability of neurons to locally express proteins at the synapse allows for a fast and effective way to control synaptic plasticity. By using subcellular fractionation, Lugli and colleagues revealed a large number of plasticity-associated miRNAs within synaptic compartments, including synaptosomes and synaptoneurosomes, as well as in post-synaptic densities. 60 The authors demonstrated the presence of miRNAs that were enriched in synaptic preparations in comparison with whole cell lysates. Synaptically located miRNAs have also been demonstrated with the use of in situ hybridization. [61] [62] [63] One of the best-studied miRNAs in the context of learning and memory is miR-132. The expression of this miRNA is associated with enhanced synaptic plasticity in the dentate gyrus as assessed by high frequency stimulation-induced long-term potentiation, which was further shown to be metabotropic glutamate receptor dependent. 64 The expression of miR-132 is induced by a variety of paradigms, including contextual fear conditioning and exposure to cocaine or odors. 40 Bredy and colleagues proposed that miR-132 may act as a proteome switch that is dependent on brain regionand/or behavioral-specific signals and may elicit different effects on synaptic plasticity mediated through its target, N-methyl-D-aspartate receptor subunit 2A. 57 As the number of studies investigating the role of miRNAs, in particular their downstream effectors (gene targets), increases, we expect the enhanced understanding of the miRNome-mRNA-protein networks to contribute to the development of novel interventions for disorders where learning and memory mechanisms are affected.
| TARGETING MIRNA IN FEAR ALLEVIATION
To date, there are far fewer studies exploring miRNA-mediated regulation during fear alleviation than fear acquisition. In the next sections, we therefore highlight specific candidate miRNAs that have been investigated either in fear alleviation by disruption of fear consolidation/reconsolidation or by extinction of fear and safety learning (Table 2) . Dissertation, Marianne Ronovsky; personal correspondence, Daniela Pollak FIGURE 3 miRNA biogenesis and function miRNAs are transcribed as primary molecules either by RNA polymerase II from independent miRNA genes or within introns of protein-coding genes. During initial processing in the nucleus, these pri-miRNAs fold into a hairpin-like structure, which in turn acts as a substrate for Drosha, a member of the RNAseIII family of enzymes. With cofactors such as DGCR8, Drosha cleaves the pri-miRNA into a 70-nucleotide-long premiRNA, which is then exported to the cytoplasm by exportin-5. Here, the second member of the RNAseIII family of enzymes, Dicer, processes it into a miRNA duplex. Dicer, along with other RNA-binding proteins, including Ago2 and TRBP, incorporates the "guide" strand into the miRNA-induced silencing complex (miRISC), while the "passenger" strand is released and degraded. ing to its long-term storage. 66 Later presentation of the CS leads to the reactivation of the original fear memory and renders it liable to future updates. This is then followed by a second phase of molecular and cellular cascades, termed "reconsolidation," ensuring that the updated fear memory is stabilized and successfully stored.
The behavioral expression of a fear memory can be modulated by various pharmacological and psychological approaches ( Figure 1 ).
Interfering with fear memory consolidation/reconsolidation is one form of disrupting the storage and expression of fear. Alternatively, fear alleviation can occur via forgetting, erasure, safety learning or the extinction of fear. 18 Forgetting-related processes involve decreases in fear with the passage of time, which is most likely due to reduced fear-memory maintenance. Fear-memory erasure involves the reversal of learning-induced changes responsible for the original CS-US association. Safety learning involves acquiring memory for specific "safety" signals that aim to reduce the fear by adding a context of safety. 67 The extinction of conditioned fear is thought to closely resemble central mechanisms of EBT in humans 68 and thus has been most extensively studied as a means to alleviate fear.
2,69,70
In some of these strategies, the critical involvement of miRNAs has been investigated, and this will now be discussed in more detail.
| Disruption of fear acquisition
The first promising strategy for the alleviation of fear is to disrupt the formation of the fear memory by preventing its acquisition or consolidation. For instance, following a traumatic event, the targeting of the initial consolidation of the resulting fear/trauma memory could prevent the development of psychopathology, including trauma-related disorders. As outlined below, one idea in the field is that interference with miRNA regulation at this point may prevent the consolidation of such aversive memories.
In line with this, Griggs and colleagues discovered that 1 and 24 hours following auditory fear conditioning in rats, miR-182 expression was decreased in the lateral amygdala (LA). 41 The authors demonstrated that this decreased expression occurred only when the CS and US were paired, indicating a fear learning-associated modulation of miR-182 expression. In further exploring a possible fundamental role in learning and memory, it was also shown that overexpression of miR-182 in the LA impaired long-term but not short-term fear memory, suggesting that miR-182 expression plays a functional role in the long-term consolidation of fear memory. Supporting the role of miR-182 in synaptic plasticity of learning and memory, the authors found that miR-182 targets actin remodeling genes that are critical to synaptic structure and memory, including cortactin and the Ras-related C3 botulinum toxin substrate 1 (Rac1).
Cortactin and Rac1 mediate synaptic strength by stabilizing actin filament branching 71 and triggering dendritic remodeling, 72 respectively. Another brain region imperative to fear processing, in particular contextual associations, is the hippocampus. 2 In exploring the role of miRNAs in the hippocampus and the association of temporally noncontiguous stimuli (using trace fear conditioning), it was discovered that miR-132 was increased 30 minutes following conditioning before returning to baseline at 2 hours. 44 Viral knockdown of miR-132 expression in the hippocampus was associated with lower freezing levels during trace fear conditioning, suggesting that inhibition of hippocampal miR-132 prevented the acquisition of fear. As mentioned above, miR-132 plays a major role in neuronal plasticity as its expression is induced by the memory-associated Ca 2+ sensitive transcription factor CREB 75 and mediates the growth of dendritic spines. 76 The use of miRNAs as therapeutic targets for the treatment of numerous disorders is undergoing increased investigation. Directly targeting miRNA levels with either mimics (agonist) or antagomirs (antagonist) provide a platform for directly modulating the expression levels of candidate miRNAs. In line with this, injection of a miR-34c mimic into the hippocampus was found to disrupt the acquisition of fear memory following contextual fear conditioning 45 suggesting the potential of miRNA mimics and/or antagomirs in the treatment of fear-related disorders. These authors also showed that the Sirt1 protein levels (the target of miR-34c) were decreased in mice that received the miR-34c mimic. Suggesting a causal link between memory impairment and miR-34c-mediated Sirt1 regulation, it was shown that protection of the Sirt1 3 0 UTR target region, using miRNA target protector sequences, was able to prevent memory impairment in mice receiving the miR-34c mimic. 45 Finally, following contextual fear conditioning, miR-92a levels are increased in the hippocampus before returning to baseline at 6 hours. 46 Enhanced expression of miR-92a an altered expression of a number of miRNAs in the amygdala. 47 Of these candidates, we revealed the regulation of miR-144-3p to be specific to extinction learning, as opposed to fear expression, and found that miR-144-3p exhibited increased amygdalar expression following extinction training in both rescued S1 and extinction-intact patients suffering from depression/anxiety. 83 The authors found that following 8 weeks of treatment using group therapy, miR-144 expression levels were normalized to healthy controls. Furthermore, it has recently been reported that miR-144 levels in peripheral blood are increased in the period preceding a "stressful exam," peaking on the day of the exam before returning to normal levels. 84 Therefore,
given that it is possible to detect levels of miR-144 in peripheral blood and expressional changes following treatment in a temporal manner, this miRNA could possibly be used as a novel biomarker in predicting treatment success for different disorders, including fearrelated disorders. In line with this, future studies examining brain and blood miRNA expression levels are needed to establish a link in miRNA expression between specific brain regions and peripheral blood. Establishing the link between brain and blood is extremely difficult and has mostly been demonstrated in diseases where the blood-brain-barrier is damaged, such as ischemia 85, 86 and Alzheimer's disease. 87 In an effort to establish a link between the brain and blood in fear-related disorders, a link between the amygdala and bloodexpression levels was demonstrated for a number of miRNAs, including miR-142-5p, miR-19b, miR-1928, miR-233 and miR-421-3p. 38 Given the correlation between brain and blood expression, this suggests that miRNA expression signatures obtained from peripheral blood could possibly be used to detect psychiatric disorders such as PTSD.
| Reconsolidation disruption
Upon retrieval, the original fear memory is brought into a labile state where it is subject to update/reconsolidation mechanisms. 88 One other approach to alleviate of fear is to interfere with reconsolidation mechanisms during this period. Demonstrating the implication of a specific miRNA in the disruption of fear-memory reconsolidation, Lin and colleagues found that following fear-extinction training in C57bl/ 6 mice, the expression levels of miR-128b were increased in the infralimbic subdivision of the medial prefrontal cortex (ILPFC). 48 The authors explored the downstream target genes and effects of increased miR-128b expression, revealing that miR-128b disrupted the stability of a number of plasticity-associated genes. These included genes that are important for the retrieval of fear memory, such as its host gene, the regulator of calmodulin signaling (RCS), which competitively inhibits calmodulin and negatively regulates protein phosphatase calcineurin activation. Virally mediated miR-128b overexpression in the ILPFC was sufficient to reduce fear responses, whereas downregulation was associated with enhanced fear expression following fear extinction training. Given that RCS-mediated downstream effects (including those on calmodulin and calcineurin signaling) normally contribute to the stability of aversive memories, miR-128b-mediated downregulation of RCS was suggested to control the transition from fear-memory retrieval to fear extinction. 48 To the best of our knowledge, this is the only study where regulation of a specific miRNA has been linked to the disruption of fear reconsolida- MiR-144-3p targeting of multiple signaling cascades successful extinction of conditioned fear is associated with increased miR-144-3p expression, which, in turn, leads to the subsequent inhibition of its target genes, including Pten, Spred1, and Notch1. This inhibition facilitates the phosphorylation of AKT/ERK and, subsequently, the activation of PI3K/AKT and MAPK/ERK signaling pathways, respectively. Phosphorylated AKT and ERK are transported to the nucleus, which leads to enhanced expression of transcription factors and plasticity-related genes such as c-fos, zif-268 and CREB. In turn, these plasticity-related genes can mediate an active chromatin state, leading to the expression of memory-associated proteins. AC, adenylyl cyclase; Ac, acetyl group; A2A, adeno-sine A2A receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; HAT, histone acetylase; HDAC, histone deacetylase; IRS, insulin receptor substrate; MEK1/2, MAPK/ ERK kinase 1/2; NMDAR, N-methyl-daspartate receptor; PDK-1, pyruvate dehydrogenase kinase 1; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-tris-phosphate; Pol III, DNA polymerase III; Ras, retrovirus-associated DNA sequences; RTK, receptor tyrosine kinase; VGCC, voltage-gated calcium channels; VMAT, vesicular monoamine transporter. Modified from Murphy et al 47 safety, which contributes to the reduction of fear responses. 18, 90 Interestingly, this type of safety learning is often impaired in patients suffering from fear-and trauma-related disorders such as PTSD 91 and respective animal models. 92 While some insights into substrates involved in safety learning have been obtained, the molecular mechanisms of learned safety remain incompletely understood. Similar to fear extinction, safety learning may also contribute to long-term fear alleviation. However, while there are certain overlaps with extinction, safety learning dissociates from extinction in various aspects, including the associated activity processing in the brain. 18 For example, in successful fear-extinction learning, specific sub-nuclei of the amygdala, including the BLA, exhibit enhanced activation, measured via immediate early genes such as c-fos, 69, 93 whereas learned safety is associated with decreased c-fos immunoreactive cells and thus with lower neuronal activity in the BLA. 67, 94 Learned safety can be studied using paradigms, where the CS (eg, tone) is explicitly dissociated from (or unpaired with) the US (eg, foot shock) during training. (Table 1 ).
This is due to the fact that brain biopsies are invasive, with increased risks for the patients, and thus most studies that do gain insight into miRNA regulation in human brain tissues come from postmortem samples of patients in whom there was increased mortality associated with the disease from which they suffered. These include neurodegenerative disorders, brain malignancies and psychiatric disorders that are associated with increased risk taking and/or suicidal tendencies, such as in schizophrenia, bipolar disorder and major depressive disorder. 96 To the best of our knowledge, there are no miRNA studies ), as in the case of retinal miRNAs, 54 or, for a select number of miRNAs, it can follow circadian patterns (for a more detailed review, see 99 ).
Finally, the delivery of miRNA-targeted therapies to the brain remains a difficult task. The use of miRNA mimics/agomirs (agonists) and miRNA antagomirs (antagonists) remains difficult due to their inability to cross the blood-brain barrier and because of possible induction of peripheral side effects. Unlike RNA, miRNAs are in general stable and often contained within exosomes (Figure 3 ) or microvesicles, which can be released from neurons and which have been found to cross the blood-brain barrier. [100] [101] [102] Addressing this issue, there is a push toward developing improved methodologies for noninvasive delivery of miRNA mimics/antagomirs to the brain. Recently a recombinant adeno-associated virus was generated that was shown to cross the blood-brain barrier in both rodents and nonhuman primates when administered intravenously. 103 Furthermore, intravenously administered gene therapy capable of crossing the bloodbrain barrier and targeting miRNAs with neuron-specific promoters was demonstrated, and shows great promise in reducing off-target side effects. 104 The use of neuron-specific promoters leads to the possibility that the modulation of a target miRNA can be restricted to neurons and even to specific neuronal subtypes. 105 Another potential method of delivery that has shown promise is intranasal administration, using small-interfering RNAs, which was shown to lead to a reduction in depression-like behavior in mice. 106 However, the noninvasive targeting of miRNA candidates in specific brain regions and possibly in specific neuronal subtypes, such as the fear "ON" or "OFF" neurons that are currently sought, remains a considerable challenge for attempts to utilize the potential of targeted miRNA-based therapeutics in fear alleviation. 
